VARICELLA: OPPORTUNITIES OF FIGHTING WITH «OLD ENEMY» IN PEDIATRIC PRACTICE

Abstract

Okavax is the first vaccine (based on strain Oka) against varicella in the world. It has high immunogenicity, provides maximally prolonged defence due to forming of cell immunity. Thus, Okavax is efficient against severe varicella. Efficiency of this vaccine is confirmed with results of studies during 20 years. Okavax has good tolerability; it can be recommended to all patients after 12 months old, especially to patients from risk groups. Key words: children, varicella, vaccination.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(5):99-102)